Prognostic factors versus predictive factors: Examples from a clinical trial of erlotinib
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
It would be helpful to have factors that could identify patients who will, or will not, benefit from treatment with specific therapies. Ideally, these should be molecular‐based factors. When results with molecular‐based factors are disappointing, physicians often use clinical characteristics to make treatment decisions. Several characteristics have been suggested to predict sensitivity to epidermal growth factor receptor inhibitors in patients with non‐small lung cancer, including gender, histology, smoking history. This report demonstrates that gender and histology are actually prognostic, rather than predictive factors. Before biomarkers or clinical characteristics are included in guidelines for selecting patients for specific treatments, it is imperative that the prognostic effects of these factors are distinguished from their ability to predict a differential clinical benefit from the specific treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419 · cited 6×
“These concepts will be illustrated by examples from National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) Study BR.21, a randomized, placebo-controlled study of erlotinib (Tarceva , OSI Pharmaceuticals Inc., Melville, NY) versus placebo for the second- or third-line treatment of patients with advanced N…”
BackgroundMethodResultInfluentialSelf-citationThatcher, N., Chang, A., Parikh, P., Rodrigues Pereira, J., Ciuleanu, T., von Pawel, J., Thongprasert, S., Tan, E. H., Pemberton, K., Archer, V., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67625-8 · Cited by 2,079 · cited 1×
“…apparent from both NCIC Study BR.21 and from the ISEL (Iressa Survival Evaluation in Lung Cancer) study of another EGFR tyrosine kinase inhibitor (Thatcher et al., 2005) that lack of tumor response does not preclude a survival benefit for this class of agents, and that it does not fully capture…”
Cited by
Prognosis Research Strategy (PROGRESS) 2: Prognostic Factor Research
Riley, R. D., Hayden, J. A., Steyerberg, E. W., Moons, K. G. M., Abrams, K., Kyzas, P. A., Malats, N., Briggs, A., Schroter, S., Altman, D. G., et al. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001380 · Cited by 823
König, I. R., Fuchs, O., Hansen, G., von Mutius, E., & Kopp, M. V. (2017) · European Respiratory Journal · doi:10.1183/13993003.00391-2017 · Cited by 572
Prognosis research strategy (PROGRESS) 4: Stratified medicine research
Hingorani, A. D., Windt, D. A. V. D., Riley, R. D., Abrams, K., Moons, K. G. M., Steyerberg, E. W., Schroter, S., Sauerbrei, W., Altman, D. G., Hemingway, H., et al. (2013) · BMJ · doi:10.1136/bmj.e5793 · Cited by 510
Predicting outcomes in radiation oncology—multifactorial decision support systems
Lambin, P., van Stiphout, R. G. P. M., Starmans, M. H. W., Rios-Velazquez, E., Nalbantov, G., Aerts, H. J. W. L., Roelofs, E., van Elmpt, W., Boutros, P. C., Granone, P., et al. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.196 · Cited by 402
The Evolving Role of Histology in the Management of Advanced Non–Small-Cell Lung Cancer
Langer, C. J., Besse, B., Gualberto, A., Brambilla, E., & Soria, J.-C. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.8126 · Cited by 300
Metadata
- Authors
- Clark, G. M.
- Venue
- Molecular Oncology
- Publisher
- Wiley
- Published
- 2007-12-08
- Volume
- 1
- Issue
- 4
- Pages
- 406-412
- ISSN
- 1574-7891 (ISSN-L)
- 1878-0261
- OpenAlex
- W2062311207
- Cited by
- 142
- References
- 2
- FWCI
- 3.65
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.